"We also saw in the high-risk group that patients who identified as Black were much more likely to not receive treatment than their White counterparts," says Madison Novosel, BA.
In this video, Madison Novosel discusses notable findings from her thesis project, “Associations between patient sociodemographic factors and non-treatment for localized prostate cancer”, which were presented at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium in San Francisco, California. Novosel is an MPH student at the Yale School of Public Health in New Haven, Connecticut.
Plant-based diets linked to lower risk of prostate cancer progression and recurrence
March 7th 2023"These findings may directly inform clinical care, such as providing diet recommendations for managing health, and potentially offer other positive health benefits for preventing numerous chronic diseases,” said Bradley Alexander McGregor, MD.
Gene therapy EG-70 shows early promise in BCG-unresponsive NMIBC
February 27th 2023"While the data are still early, EG-70's safety profile and efficacy are well on their way towards establishing a new benchmark for monotherapy treatment of high-risk NMIBC with BCG-unresponsive carcinoma in situ,” said lead study author Gary Steinberg MD.
Salvage nivolumab/ipilimumab effective in RCC patients unresponsive to upfront nivolumab
February 21st 2023Patients with renal cell carcinoma who had progressive disease or stable disease after frontline nivolumab had a substantial treatment-free survival period following salvage immunotherapy with nivolumab plus ipilimumab.
Real-world study investigates first-line avelumab maintenance for metastatic urothelial carcinoma
February 20th 2023Baseline findings showed that patients treated with first-line platinum-based chemotherapy prior to avelumab maintenance experienced a complete response rate of 13% and a partial response rate of 68% to chemotherapy.
2 Clarke Drive
Cranbury, NJ 08512